1. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study
- Author
-
Ronald Zolty, Ninel Hovnanians, Parham Eshtehardi, Luise Holzhauser, David Goodman-Meza, Yi-An Ko, Pavlos Msaouel, Yi Deng, and M. Khalid Mojadidi
- Subjects
Male ,medicine.medical_specialty ,Statin ,medicine.drug_class ,Heart Ventricles ,Hypertension, Pulmonary ,030204 cardiovascular system & hematology ,Severity of Illness Index ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,Cause of Death ,Internal medicine ,medicine ,Humans ,Pulmonary Wedge Pressure ,Propensity Score ,Intensive care medicine ,Pulmonary wedge pressure ,Survival rate ,Aged ,Retrospective Studies ,COPD ,Ejection fraction ,business.industry ,medicine.disease ,Pulmonary hypertension ,Echocardiography, Doppler ,Hospitalization ,Survival Rate ,Blood pressure ,030228 respiratory system ,Propensity score matching ,Female ,New York City ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Cardiology and Cardiovascular Medicine ,business - Abstract
Inflammation is an increasingly recognized hallmark of pulmonary hypertension (PH). Statins have been shown to attenuate key pathologic mechanisms via pleiotropic effects in animal models. However, clinical benefit of statins in patients with PH is unknown and their effect on mortality has not been studied. We performed a retrospective analysis of patients between January 2002 to January 2012, with severe PH (pulmonary artery systolic pressure ≥60 mmHg) and preserved left ventricular function (ejection fraction ≥50%), defined by transthoracic echocardiograms. Patients were divided into two groups based on statin therapy for 12 consecutive months after diagnosis of PH. Propensity score matching was performed. Subgroup analysis was done based on COPD status. Study endpoint was 1-year all-cause mortality and hospitalization. 2363 patients (age 71 ± 16; 31% male) were included; 140 (6%) were on statin therapy. Overall 1-year mortality was 34%. Following propensity score matching, 138 patients were included in the statin group and 624 patients in the no-statin group; all-cause mortality was significantly lower in the statin group compared with the no-statin group [15.2 vs. 33.8%, HR 0.42 (95% CI 0.27, 0.66), p
- Published
- 2017
- Full Text
- View/download PDF